Earnings Results
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings results on November 03, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $0.18, beating the consensus estimate of $0.17 by $0.01 per share. Revenue came in at $37.8M, beating the estimate of $37.3M.
Company Overview
Zevra Therapeutics's stock moved following the earnings release. The stock currently trades at $11.17 with a market capitalization of $472.3M.
Zevra Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Zevra Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Zevra Therapeutics Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q3 (Nov 2026) | $0.18 | $0.17 | +3.5% |
| Q2 (Aug 2026) | $0.25 | $0.14 | +78.6% |
| Q1 (May 2026) | $0.18 | $0.08 | +125.0% |
| Q4 (Mar 2026) | $0.19 | $0.05 | +280.0% |
Related Tools: Earnings Calendar | View ZVRA Stock Page
Frequently Asked Questions
When does Zevra Therapeutics report earnings?
Check the latest earnings dates on our ZVRA earnings page or the Earnings Calendar.
Did ZVRA beat earnings estimates?
See the full Q3 results including EPS actual vs estimate on our ZVRA earnings page.